Descrizione
Relative abundance of key bacterial taxa is compared between synbiotic and placebo groups, highlighting Lactobacillus and Bifidobacterium dynamics.
Figure 28
ChartSource Paper
The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant …Cite This Figure
![Figure 28: Relative abundance of key bacterial taxa is compared between synbiotic and placebo groups, highlighting Lactobacillus and Bifidobacterium dynamics.]() > Source: Barbara Skrzydło-Radomańska et al. "The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidoba." *Nutrients*, 2020. PMID: [32635661](https://pubmed.ncbi.nlm.nih.gov/32635661/)
<figure> <img src="" alt="Relative abundance of key bacterial taxa is compared between synbiotic and placebo groups, highlighting Lactobacillus and Bifidobacterium dynamics." /> <figcaption>Figure 28. Relative abundance of key bacterial taxa is compared between synbiotic and placebo groups, highlighting Lactobacillus and Bifidobacterium dynamics.<br> Source: Barbara Skrzydło-Radomańska et al. "The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidoba." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32635661/">32635661</a></figcaption> </figure>
Evidenze correlate
B
Bifidobacterium longum per Irritable Bowel Syndrome (IBS)
B
Grado B · 4 studi
Galactooligosaccharides (GOS) per Irritable Bowel Syndrome (IBS)
B
Grado B · 3 studi
Lactobacillus acidophilus per Irritable Bowel Syndrome (IBS)
D
Grado B · 3 studi
Fructooligosaccharides (FOS) per Irritable Bowel Syndrome (IBS)
Grado D · 2 studi